%0 Journal Article %A Eli P. Fenichel %A Anna Gilbert %A Gregg Gonsalves %A Anne L. Wyllie %T Understanding the barriers to pooled SARS-CoV-2 testing in the United States %D 2021 %R 10.1101/2021.04.17.21255440 %J medRxiv %P 2021.04.17.21255440 %X Pooled testing for SARS-CoV-2 detection is instrumental for increasing test capacity while decreasing test cost, key factors for sustainable, long-term surveillance measures. While numerous pooled approaches have been described, uptake by labs has been limited. We surveyed 90 US labs to understand the barriers to implementing pooled testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors %U https://www.medrxiv.org/content/medrxiv/early/2021/04/22/2021.04.17.21255440.full.pdf